Heart Smart: A Virtual Self-Management Program for Homebound People With Heart Failure

Sponsor
University of Pennsylvania (Other)
Overall Status
Completed
CT.gov ID
NCT05057364
Collaborator
(none)
5
1
1
3.1
1.6

Study Details

Study Description

Brief Summary

The purpose of this capstone project is to pilot Heart Smart, a virtual group program to improve self-efficacy for self-management skills for homebound people with heart failure.

Condition or Disease Intervention/Treatment Phase
  • Other: Heart Smart Virtual Self-Management Group
N/A

Detailed Description

The purpose of this capstone project is to pilot Heart Smart, a virtual group program to improve self-efficacy for self-management skills for homebound people with heart failure. Heart Smart will provide synchronous virtual group education to homebound people with heart failure receiving services from Penn Medicine at Home. The primary clinical goal is to improve self-efficacy for heart failure self-management and improve their knowledge of heart failure self-management strategies. Secondary outcomes will explore the feasibility of the program by exploring technology, adherence and satisfaction with the program.

Study Design

Study Type:
Interventional
Actual Enrollment :
5 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Intervention Model Description:
Pilot study, single group, no control. pre-post data collectionPilot study, single group, no control. pre-post data collection
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Heart Smart: A Virtual Self-Management Program for Homebound People With Heart Failure
Actual Study Start Date :
Sep 28, 2021
Actual Primary Completion Date :
Dec 31, 2021
Actual Study Completion Date :
Dec 31, 2021

Arms and Interventions

Arm Intervention/Treatment
Experimental: Heart Smart Group

Receives Heart Smart Intervention

Other: Heart Smart Virtual Self-Management Group
The Heart Smart Intervention is a 6 week virtual program consisting of one individual technology training session followed by 5 one hour group education sessions.

Outcome Measures

Primary Outcome Measures

  1. Change in Self-Efficacy Measure for Chronic Disease (SEMCD) [At first and final sessions (weeks 1 and 6)]

    This self-report scale has 6 items which are each rated on a scale of 1 (not at all confident) to 10 (totally confident). The score for the scale is the mean of the scores for the six items. Possible scores are 1-10 with higher scores indicating higher self-efficacy. This scale is an appropriate outcome measure for a heart failure self-management group because it was designed to measure self-efficacy in people with chronic conditions such as heart failure and has undergone psychometric evaluation. This scale is free to use without permission. Administration takes less than 10 minutes.

Secondary Outcome Measures

  1. Change in Kansas City Cardiomyopathy Questionnaire (KCCQ) [At first and final sessions (weeks 1 and 6)]

    This 23-item, Likert scale, self-report heart failure specific outcome measure. The instrument measures six domains: physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge, and quality of life. This instrument is appropriate because it is designed for use for people with heart failure, will give an indication of participant heart failure severity for demographic purposes, and has a validated self-efficacy component. This scale requires a license which has been obtained for this pilot project. Administration takes less than 10 minutes. Scores range from 0 to 100 with higher scores indicating higher cardiac health status.

  2. Change in Atlanta Heart Failure Knowledge Test V3 (AHFKT) [At first and final sessions (weeks 1 and 6)]

    This 30 item multiple choice measure of heart failure self-management knowledge yields scores 0-30 which are commonly reported as a percentage (higher scores indicate more knowledge). Content validity was established through a panel of expert heart failure nurses.

Other Outcome Measures

  1. Attendance [At each weekly session for 6 weeks]

    The number of participants at each meeting will be recorded.

  2. Minutes of training [This will be recorded in the first session at week 1.]

    The number of minutes spent in the pre-training session will be recorded.

  3. Participant Satisfaction [At the final session on week 6]

    Participants will answer three likert scale questions.

  4. Technology failures [At each weekly session for 6 weeks.]

    Total number of minutes missed per participant per session.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Diagnosis of heart failure

  • Receiving home health care from Penn Medicine at Home at time of screening.

  • Technology capabilities to participate in the program (laptop or tablet with a camera, internet access).

  • Able to read and write in English.

  • Cognitive ability to participate in the program if the participant is able to score12/15 on the Montreal Cognitive Assessment (MoCA) 5 Minute Phone Test.

Exclusion Criteria:
  • Hearing impairment that impacts communication.

  • Previous experience receiving occupational therapy services from the principal investigator.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Penn Medicine at Home Bala-Cynwyd Pennsylvania United States 19004

Sponsors and Collaborators

  • University of Pennsylvania

Investigators

  • Principal Investigator: Sara Frye, MS OTR/L ATP, Penn Medicine at Home Professional Development Department

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Sara Frye, MS OTR/L ATP, Therapy Professional Development Specialist, University of Pennsylvania
ClinicalTrials.gov Identifier:
NCT05057364
Other Study ID Numbers:
  • 849646
First Posted:
Sep 27, 2021
Last Update Posted:
Mar 9, 2022
Last Verified:
Mar 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Sara Frye, MS OTR/L ATP, Therapy Professional Development Specialist, University of Pennsylvania
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 9, 2022